IGF-1 DES exhibits moderate side effects, low oral and excellent subcutaneous bioavailability in mice
It can be a game-changer for natural growth hormone optimization when used under professional guidance
The primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning insulin is only released when blood glucose levels are elevated Suppressing glucagon release from pancreatic alpha cells, which reduces hepatic glucose production Slowing gastric emptying , which helps moderate post-meal blood glucose spikes Reducing appetite through central nervous system effects, leading to decreased caloric intake and weight loss Examples of GLP-1 receptor agonists available in the UK include exenatide (Byetta, Bydureon), liraglutide (Victoza for diabetes, Saxenda for weight management), dulaglutide (Trulicity), lixisenatide (Lyxumia), and semaglutide (Ozempic/Rybelsus for diabetes, Wegovy for weight management)
Tettamanti et al
Common areas of laboratory investigation include
For example, exenatide intake was associated with weight loss and reduction in levels of HbA1c, systolic blood pressure, triglycerides, and high-sensitivity CRP in obese patients with type 2 diabetes on insulin [132]